摘要:
Systems, architectures, and data structures are described which are used to manage distributed design chains, specifically for domains in which data reside in multiple applications and are linked through complex interrelationships. The design chains or design networks integrated by the invention may include multiple companies in multiple sites collaborating to design and develop a new product. The invention is intended to integrate seamlessly and transparently with existing, diverse legacy applications, which include inter-linked data relevant to the design, thereby addressing the needs identified above.
摘要:
Systems, architectures, and data structures are described which are used to manage distributed design chains, specifically for domains in which data reside in multiple applications and are linked through complex interrelationships. The design chains or design networks integrated by the invention may include multiple companies in multiple sites collaborating to design and develop a new product. The invention is intended to integrate seamlessly and transparently with existing, diverse legacy applications, which include inter-linked data relevant to the design, thereby addressing the needs identified above.
摘要:
Systems, architectures, and data structures are described which are used to manage distributed design chains, specifically for domains in which data reside in multiple applications and are linked through complex interrelationships. The design chains or design networks integrated by the invention may include multiple companies in multiple sites collaborating to design and develop a new product. The invention is intended to integrate seamlessly and transparently with existing, diverse legacy applications, which include inter-linked data relevant to the design, thereby addressing the needs identified above.
摘要:
A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.
摘要:
A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period over which the dosage form provides a plasma concentration within the therapeutic range of diphenhydramine or salt thereof. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
摘要:
A pharmaceutical dosage form which comprises a first drug which comprises at least one morphine derivative with antitussive activity and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of the first drug. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
摘要:
A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period over which the dosage form provides a plasma concentration within the therapeutic range of diphenhydramine or salt thereof. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
摘要:
A pharmaceutical dosage form which comprises carbetapentane and/or a pharmaceutically acceptable salt thereof and an additional drug. The dosage form provides a plasma concentration within the therapeutic range of the additional drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of carbetapentane. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
摘要:
A pharmaceutical dosage form which comprises phenylepherine or a pharmaceutically acceptable salt thereof and a second drug. The dosage form provides a plasma concentration within the therapeutic range of the second drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of phenylepherine. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
摘要:
An apparatus comprising a mode circuit and an encryption circuit. The mode circuit may be configured to selectively provide register input data on an output signal when in a first mode and memory data on the output signal when in a second mode. The encryption circuit may be configured to interchangeably encrypt/decrypt between the register input data and the memory data.